# TLN-372 in Advanced KRAS Mutant Solid Tumors

Source: https://onco.cc/trials/nct07204340/  
OnCo record `nct07204340` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of TLN-372 run by Treeline Biosciences, Inc., now recruiting.

## Summary

TLN-372 in Advanced KRAS Mutant Solid Tumors is a phase 1 interventional study registered as NCT07204340 by Treeline Biosciences, Inc., with 270 participants planned, started 2025-09-29. Conditions recorded: KRAS Mutant Solid Tumors. Interventions recorded: TLN-372, TLN-372 in combination with cetuximab and TLN-372 in combination with pembrolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07204340
- Phase: 1
- Setting: An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination With Other Anti-Tumor Agents, in Patients With Advanced KRAS Mutant Solid Tumors
- Sponsor: Treeline Biosciences, Inc.
- Enrolled: 270

## Sources

- ClinicalTrials.gov NCT07204340: https://clinicaltrials.gov/study/NCT07204340

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [TLN-372](https://onco.cc/drugs/tln-372/)
- companies: [Treeline Biosciences](https://onco.cc/companies/treeline-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct07204340.json